Semax half-life & pharmacokinetics

Reported half-life

Very short plasma half-life (~minutes) due to rapid peptidase degradation; the practical pharmacology is dominated by intranasal delivery achieving direct olfactory and trigeminal pathway access to the central nervous system, where cerebrospinal fluid and hippocampal tissue concentrations are sustained for substantially longer than peripheral plasma exposure suggests. Functional cognitive effects from a single intranasal dose persist for 4-8 hours despite the short plasma half-life.

The half-life and pharmacokinetic profile of Semax reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Intranasal (standard research and clinical route)
• Subcutaneous injection (pre-clinical research)
• Intravenous infusion (acute stroke clinical research)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic heptapeptide analogue of ACTH(4-10); melanocortin-receptor-related cognitive enhancer with BDNF/NGF-upregulating activity.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Semax acts as follows:

Semax is a 7-amino-acid synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP) derived from the central biologically active region of adrenocorticotropic hormone (ACTH) by truncation of the 4-10 sequence and addition of a C-terminal Pro-Gly-Pro tripeptide that confers proteolytic stability. The native ACTH 4-10 sequence (MEHFRWG) was identified in the mid-20th century as the minimal region of ACTH retaining nootropic and neuroprotective activity without the corticotropic (adrenocortical-stimulating) effect of the full ACTH molecule. Semax represents a deliberate medicinal-chemistry optimisation of this fragment for stability and nootropic potency.

See the full Semax research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.